SNGX SOLIGENIX, INC.

Nasdaq www.soligenix.com


$ 1.59 nm (nm)    

Wednesday, 15-Oct-2025 17:25:35 EDT
QQQ $ 602.02 $ 4.22 (0.71 %)
DIA $ 462.40 $ 0.00 (0 %)
SPY $ 664.98 $ 2.94 (0.44 %)
TLT $ 90.80 $ -0.20 (-0.22 %)
GLD $ 387.26 $ 6.60 (1.73 %)
$ 1.63
$ 1.64
$ 1.58 x 532
$ 1.70 x 342
$ 1.56 - $ 1.66
$ 1.09 - $ 6.23
418,042
na
6.99M
$ 0.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-21-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-18-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-26-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-27-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-24-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 soligenix-updates-us-medical-advisory-board-to-guide-phase-3-hybryte-development-for-ctcl

Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical DevelopmentPRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- S...

 soligenix-reports-no-safety-concerns-in-first-dmc-review-of-phase-3-hybryte-trial-for-ctcl

FLASH2 Study Interim Efficacy Analysis Targeted for 1H2026Enrollment Update Remains on Track for 4Q2025PRINCETON, N.J., Oct. 7,...

 soligenix-expands-european-mab-to-provide-addl-medicalclinical-strategic-guidance-as-it-advances-confirmatory-phase-3-placebo-controlled-study-evaluating-safety-and-efficacy-of-hybryte-in-ctcl-treatment

In preparation for health authority interactions in pursuit of marketing approvals in Europe  PRINCETON, N.J., Sept. 30, 2025 /...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 soligenix-publishes-study-proving-long-term-stability-of-thermovax-ebola-vaccines

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and comm...

 thermostable-bivalent--trivalent-filovirus-vaccines-from-insect-cells-potency-demonstrated-after-3-months-and-2-years--science-direct

https://www.sciencedirect.com/science/article/abs/pii/S0264410X25009818

 5-healthcare-stocks-on-fire-this-week

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech &...

 watching-soligenix-zacks-small-cap-research-gives-stock-3500-price-valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08202025_SNGX_Bautz.pdf

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION